表紙画像

Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)

Background: The in-hospital treatment for COVID-19 may include medicines from various therapeutic classes, such as antiviral remdesivir and immunosuppressant tocilizumab. Safety data for these medicines are based on controlled clinical trials and case reports, limiting the knowledge about less frequ...

保存先:

書誌詳細
主要な著者:	Beatriz Marinho Silva Romão (著者), Felipe Vieira Duval (著者), Elisângela Costa Lima (著者), Fabrício Alves Barbosa da Silva (著者), Guacira Correa de Matos (著者)
フォーマット:	図書
出版事項:	Frontiers Media S.A., 2024-01-01T00:00:00Z.
主題:	article
オンライン･アクセス:	Connect to this object online.
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
著者:: Ming-Tao Wen, 等
出版事項: (2024)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
著者:: Yunyan Pan, 等
出版事項: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
著者:: Yue He, 等
出版事項: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
著者:: Xusheng Zhang, 等
出版事項: (2024)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
著者:: Yiwen Bao, 等
出版事項: (2024)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
著者:: Si Su, 等
出版事項: (2023)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
著者:: Pan Ma, 等
出版事項: (2022)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
著者:: Jiahong Zhong, 等
出版事項: (2024)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
著者:: Jianxing Zhou, 等
出版事項: (2022)

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
著者:: Ruibo Li, 等
出版事項: (2024)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
著者:: Fan Zou, 等
出版事項: (2023)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
著者:: Lin Zhang, 等
出版事項: (2023)

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
著者:: Liyuan Liu
出版事項: (2024)

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
著者:: KaiLi Mao, 等
出版事項: (2024)

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
著者:: Dan Liu, 等
出版事項: (2024)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
著者:: Wenqiang Kong, 等
出版事項: (2023)

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
著者:: Shangze Li, 等
出版事項: (2024)

A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)
著者:: Jie Zhou, 等
出版事項: (2024)

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022
著者:: Marwan A. Alrasheed, 等
出版事項: (2024)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
著者:: Alexandra A. Taube, 等
出版事項: (2020)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
著者:: Dan Zhao, 等
出版事項: (2024)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
著者:: Linlin Tang, 等
出版事項: (2024)

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
著者:: Jinger Lin, 等
出版事項: (2024)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
著者:: Zhuo Ma, 等
出版事項: (2021)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
著者:: Zhiwei Cui, 等
出版事項: (2023)

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
著者:: Stefania Chiappini, 等
出版事項: (2023)

Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database
著者:: Fei W, 等
出版事項: (2023)

Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database
著者:: Xiping Yang, 等
出版事項: (2024)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
著者:: Rania M. Sarhan, 等
出版事項: (2022)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
著者:: Junwei Wang, 等
出版事項: (2024)

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups
著者:: Yingyong Ou, 等
出版事項: (2024)

Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups
著者:: Xin Guan, 等
出版事項: (2024)

Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023
著者:: Yihan Yang, 等
出版事項: (2024)

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
著者:: Ali F. Altebainawi, 等
出版事項: (2023)

A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database
著者:: Huanying Xu, 等
出版事項: (2024)

Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）
著者:: Zicheng Yu, 等
出版事項: (2022)

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
著者:: Khalidah A. Alenzi, 等
出版事項: (2024)

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database
著者:: Xinnan Chen, 等
出版事項: (2024)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
著者:: Risako Hirai, 等
出版事項: (2023)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
著者:: Yanjing Zhang, 等
出版事項: (2024)